Forbes | Nov 10 | Rivaroxaban, a powerful new blood thinner in late-stage tests in heart patients at J&J and Bayer, is J&J’s hope as a potential huge bestseller to revive its slumping drug unit, despite significantly higher rates of bleeding in patients who took the drug. Forbes